News

The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license ...
Genentech, part of the Roche Group ( OTCQX:RHHBY) ( OTCQX:RHHBF) ( OTCPK:RHHVF ), announced that the U.S. FDA has rejected ...
Here's what lies ahead Drug giant promises $50 billion U.S. investment Drug giant promises $50 billion U.S. investment Bay ...
Genentech is planning a massive overhaul of its 207-acre South San Francisco campus that could cost between $3B and $5B by the time the multiphase project is complete, according to the San Francisco ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall s ...
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial ...
Genentech will withdraw Gavreto from use in the United States for treating a type of thyroid cancer as it was not feasible for the Roche unit to pursue the drug for full approval, its partner ...
How Genentech and other drug makers are stepping up the game in how they interact with patients.
Genentech, where Stanford President Marc Tessier-Lavigne once served as chief scientific officer, confirmed on Thursday that there were concerns about Alzheimer’s research Tessier-Lavigne co ...
SOUTH SAN FRANCISCO, Calif., January 28, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the overall survival (OS) analysis ...
Genentech, a member of the Roche Group, today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’ s artificial intelligence capabilities, extensive ...